We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Read MoreHide Full Article
Armata Pharmaceuticals, Inc. (ARMP - Free Report) shares rallied 12.2% in the last trading session to close at $5.06. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.3% loss over the past four weeks.
Armata Pharmaceutical's stock price gained after the company advanced AP-SA02, its investigational bacteriophage therapy for Staphylococcus aureus bacteremia, toward a planned phase III superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA) in the second half of 2026. The company submitted the complete phase III protocol and comprehensive responses to all FDA feedback received after its end-of-phase II meeting, addressing clinical, CMC, and regulatory requirements. It also completed four engineering manufacturing runs at its in-house cGMP facility, marking an important phase III readiness milestone. These advancements position Armata to initiate its pivotal phase III study, which is intended to support a future biologics license application for AP-SA02.
This company is expected to post quarterly loss of $0.48 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $0.84 million, down 61.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Armata Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARMP going forward to see if this recent jump can turn into more strength down the road.
Armata Pharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Niagen Bioscience (NAGE - Free Report) , finished the last trading session 2.7% higher at $3.37. NAGE has returned -6.3% over the past month.
Niagen Bioscience's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.01. Compared to the company's year-ago EPS, this represents a change of -75%. Niagen Bioscience currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Armata Pharmaceuticals, Inc. (ARMP - Free Report) shares rallied 12.2% in the last trading session to close at $5.06. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.3% loss over the past four weeks.
Armata Pharmaceutical's stock price gained after the company advanced AP-SA02, its investigational bacteriophage therapy for Staphylococcus aureus bacteremia, toward a planned phase III superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA) in the second half of 2026. The company submitted the complete phase III protocol and comprehensive responses to all FDA feedback received after its end-of-phase II meeting, addressing clinical, CMC, and regulatory requirements. It also completed four engineering manufacturing runs at its in-house cGMP facility, marking an important phase III readiness milestone. These advancements position Armata to initiate its pivotal phase III study, which is intended to support a future biologics license application for AP-SA02.
This company is expected to post quarterly loss of $0.48 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $0.84 million, down 61.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Armata Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARMP going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Armata Pharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Niagen Bioscience (NAGE - Free Report) , finished the last trading session 2.7% higher at $3.37. NAGE has returned -6.3% over the past month.
Niagen Bioscience's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.01. Compared to the company's year-ago EPS, this represents a change of -75%. Niagen Bioscience currently boasts a Zacks Rank of #3 (Hold).